Results 21 to 30 of about 28,723 (210)
Enoxaparin vs Fondaparinux Dalam Penurunan CK-MB [PDF]
, 2020 Ischemic Heart Disease (Non ST Elevated Myocardial Infarction-NSTEMI) is the leading cause of death in Indonesia after Stroke. Enoxaparin and Fondaparinux are the drugs of choice for this condition.
sukmawan, yedy purwandi +2 more
core +1 more source
Dose-dependent neuroprotective effect of enoxaparin on cold-induced traumatic brain injury
Neural Regeneration Research, 2017 Recent evidence exists that enoxaparin can reduce brain injury because of its anticoagulant activity. To investigate the potential therapeutic effect of enoxaparin on cold-induced traumatic brain injury, at 20 minutes after modeling, male BALB/c mouse ...
Ilknur Keskin +5 more
doaj +1 more source
Comparative study: Post-operative variables (branded enoxaparin vs biosimilar enoxaparin groups).
, 2023 Comparative study: Post-operative variables (branded enoxaparin vs biosimilar enoxaparin groups).
Chadli Dziri (14048856) +7 more
core +1 more source
A complication of enoxaparin injection [PDF]
Cleveland Clinic Journal of Medicine, 2019 Computed tomography revealed a hematoma measuring 15 by 15 cm compressing the bladder and causing hydronephrosis.
Ahmad Muneer, Sharayah +3 more
openaire +2 more sources
, 2023 Comparative study: Pre and intraoperative variables (branded enoxaparin vs biosimilar enoxaparin groups).
Chadli Dziri (14048856) +7 more
core +1 more source
Enoxaparin-induced hepatotoxicity: an under-recognised complication of enoxaparin therapy [PDF]
BMJ Case Reports, 2016 Low-molecular-weight heparins including enoxaparin are commonly used for anticoagulation as prophylaxis and treatment for deep vein thrombosis (DVT). Prescribers of enoxaparin monitor for common side effects, such as bleeding and thrombocytopenia, but hepatotoxicity, a less common and under-reported adverse effect, may be overlooked.
Katie Ann, Pivarnik +3 more
openaire +2 more sources
Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
Clinical Medicine Insights: Blood Disorders, 2019 Background: The appropriate dose of enoxaparin for venous thromboembolism (VTE) prophylaxis in low body weight patients is unknown. Objective: The aim of this study is to evaluate the impact of enoxaparin dosing on major and minor bleeding events in low ...
Daniel Dybdahl +4 more
doaj +1 more source
Plasmatology, 2023 Background Although reduced doses of enoxaparin have been studied in low body weight patients, no study has directly compared enoxaparin to unfractionated heparin for venous thromboembolism (VTE) prophylaxis in this population. Objective To determine the
David Michael Kaylor PharmD +4 more
doaj +1 more source
Archives of Anesthesia and Critical Care, 2020 Background: The use of subcutaneous enoxaparin is a usual method for preventing venous thromboembolism (VTE) in the intensive care unit (ICU) patients, but adequate absorption of the drug is not reliable due to the illness intensity, existing edema and ...
Masoum Khoshfetrat +3 more
doaj +1 more source
Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports
Frontiers in Pharmacology, 2018 Lichen planus (LP) is an uncommon mucocutaneous inflammatory condition, that is immunologically mediated, typically pruritic and often recurs. The currently advocated therapies are either not highly effective or associated with severe side effects ...
Rahul P. Patel +6 more
doaj +1 more source